摘要
目的探讨黏膜相关淋巴瘤的临床特征、治疗及预后。方法收集1998--2008年期间的48例黏膜相关淋巴瘤的临床资料。结果48例中，中位年龄46岁（15—82岁），原发部位依次为胃肠道、眼眶、甲状腺、腮腺、韦氏环、乳腺、肺，全组病例没有B症状，PS评分≥2仅4例，伴LDH升高2例，Arbor分期Ⅲ、Ⅳ期共9例，淋巴瘤国际预后指数IPI评分≥2有4例，单纯手术或局部放疗23例，局部治疗联合化疗21例，单纯化疗4例，治疗后完全缓解率70．8％，总有效率100％。随访3—180个月（中位51个月），有11例复发，伴有大细胞转化2例，死亡2例，5年总生存率94．2％，5年无进展生存78．2％，单因素分析显示：影响无进展生存的预后因素为Arbor分期Ⅲ、Ⅳ期，而与是否接受化疗及近期疗效无关。结论黏膜相关淋巴瘤是一种可侵犯结外多种器官的惰性淋巴瘤，预后不利因素少，单纯手术或放疗可获长期生存，本组中影响无进展生存的预后因素为Arbor分期Ⅲ、Ⅳ期，而与是否接受化疗及近期疗效无关。
Objective To investigate the clinical characteristics, treatment and prognosis of patients with MALT lymphomas. Methods Retrospective study was done in 48 patients with MALT lymphomas. Results Of the 48 patients, 29 cases were men and 19 cases were women, of ages ranged from 15 to 82（median： 46 years old）. The most frequent locations were gastrointestinal tract, orbit, thyroid, parotid, Waldeyer＇s ring, breast and lungs in turn; none was presence of B symptoms; 2 had locate dehydrogenase elevation; PS ≥2 was seen in 4 patients; IPI≥2 in 4 patients; 9 at stage Ⅲ or IV ; 23 received radiotherapy or surgery, 21 received combined chemotherapy, 4 received chemotherapy alone; 34 achieved complete remission （CR） after scheduled treatment, 14 achieved partial remission（PR）, the median survival time was 89 months, 11 relapsed, 2 showed transformation to large B-cell, 2 died; the 5-year overall survival rate was 94.2% , the 5-year progression-free survival was 78.2% , stage Ⅲ/IV predicted poor progression-free survival in unvarite analysis. Conclusion Most MALT lymphoma patients present at diagnosis with an indolent disease with good performance status （PS） , absence of B symptoms, and few adverse biological prognostic factors, and long survival, stage Ⅲ/IV predicted poor progression-free survival.
出处
《肿瘤基础与临床》
2008年第6期513-515,共3页
journal of basic and clinical oncology
关键词
MALT淋巴瘤
临床特征
治疗
预后
MALT lymphomas
clinical characteristics
therapy
prognosis
